1. RAPID AND DURABLE RESPONSES WITH THE SYK/JAK INHIBITOR CERDULATINIB IN A PHASE 2 STUDY IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA—ALONE OR IN COMBINATION WITH RITUXIMAB. (12th June 2019) Authors: Smith, S.D.; Munoz, J.; Stevens, D.A.; Smith, S.M.; Feldman, T.A.; Ye, J.C.; de Vos, S.; Hess, B.T.; Miller, C.B.; Khatcheressian, J.L.; Birrell, M.R.; Leeds, J.M.; Coffey, G.P.; Conley, P.B.; Michelson, G.C.; Curnutte, J.T.; Hamlin, P.A. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 61 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. INCIDENCE AND TREATMENT OUTCOMES OF PATIENTS WITH TRANSFORMED MARGINAL ZONE LYMPHOMA TREATED WITH RCHOP‐LIKE REGIMENS. (12th June 2019) Authors: Rajeeve, S.; Bobillo, S.V.; Zelenetz, A.D.; Straus, D.J.; Palomba, M.L.; Noy, A.; Horwitz, S.M.; Moskowitz, A.J.; Hamlin, P.A.; Matasar, M.J.; Kumar, A.; Batlevi, C.L.; von Keudell, G.; Yahalom, J.; Dogan, A.; Drill, E.; Younes, A.; Joffe, E. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 264 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. A PILOT STUDY OF BRENTUXIMAB VEDOTIN AND AVD CHEMOTHERAPY FOLLOWED BY 20 GY INVOLVED‐SITE RADIOTHERAPY IN EARLY STAGE, UNFAVORABLE RISK HODGKIN LYMPHOMA. (June 2017) Authors: Kumar, A.; Casulo, C.; Advani, R.; Budde, E.; Barr, P.M.; Batlevi, C.L.; Chen, R.; Constine, L.S.; Courtien, A.I.; Dandapani, S.V.; Drullinsky, P.; Friedberg, J.W.; Hamlin, P.A.; Hoppe, R.T.; Matasar, M.J.; McArthur, G.N.; Miller, S.T.; Moskowitz, A.J.; Noy, A.; Schoder, H. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 171 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. THE DUAL SYK/JAK INHIBITOR CERDULATINIB DEMONSTRATES RAPID TUMOR RESPONSES IN a PHASE 2 STUDY IN PATIENTS WITH RELAPSED/REFRACTORY B‐CELL MALIGNANCIES. (June 2017) Authors: Hamlin, P.A.; Farber, C.M.; Fenske, T.S.; Khatcheressian, J.L.; Miller, C.B.; Munoz, J.; Patel, M.R.; Schreeder, M.T.; Smith, S.M.; Stevens, D.A.; Pandey, A.; Birrell, M.R.; Leeds, J.M.; Wang, Y.L.; Coffey, G.P.; Curnutte, J.T. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 74 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. BASELINE METABOLIC TUMOR VOLUME IS AN INDEPENDENT PROGNOSTIC FACTOR FOR RELAPSED AND REFRACTORY HODGKIN LYMPHOMA PATIENTS RECEIVING PET‐ADAPTED SALVAGE THERAPY WITH BRENTUXIMAB VEDOTIN AND AUGMENTED ICE. (June 2017) Authors: Moskowitz, A.J.; Schöder, H.; Gavane, S.; Thoren, K.L.; Fleisher, M.; Yahalom, J.; McCall, S.J.; Fox, S.Y.; Gerecitano, J.; Grewal, R.; Hamlin, P.A.; Horwitz, S.; Kumar, A.; Matasar, M.; Ni, A.; Noy, A.; Palomba, M.L.; Perales, M.; Portlock, C.S.; Sauter, C. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 36 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗